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A patient-tailored treatment approach demands 
precise determin ation of initial disease extent 
combined with early, accurate assessment of response 
to treatment. Positron emission tomography/com-
puted tomography (PET/CT) is currently the most 
widely used molecular imaging technology and is central to the 
advancement of patient care and biological research.[1,2]
PET/CT whole-body imaging
PET is a non-invasive tool that provides tomographic images and 
quantitative parameters of perfusion, cell viability, and proliferation 
and/or metabolic activity of tissues. These images result from 
the use of various biological compounds (such as sugars, amino 
acids, metabolic precursors and hormones) labelled with positron-
emitting radionuclides (PET radiopharmaceuticals).[1] Fusion of the 
functional information with the morphological detail provided by 
CT as PET/CT can provide clinicians with a sensitive and accurate 
one-step whole-body diagnostic and prognostic tool, which directs 
and changes patient management.[1,3]
Several studies have demonstrated the superiority of combined 
PET/CT over either modality alone, and for many indications this is 
generally accepted as the gold standard for imaging in oncol ogy. [4] 
The value of PET/CT imaging has been best demonstrated in the 
setting of oncology with the use of fluorine-18-fluorodeoxyglucose 
(18F-FDG). FDG is an analogue of glucose and is taken up by cells 
via the first stages of the normal glucose pathway and trapped inside 
cells with high glucose transporter expression and/or glycolytic 
activity. Tumour uptake therefore correlates with tumour growth and 
viability, providing metabolic quantification and frequently useful 
information for tumour characterisation, patient prognosis and 
monitoring of therapeutic response.[1]
Impact on the management of 
oncology patients
Current data suggest that in as many as one-third to one-half of cancer 
cases, physicians without access to PET are at an increased risk of 
selecting the wrong management/treatment strategy for their patients. 
Three large-scale national studies published by the National Oncologic 
PET Registry in the USA have shown that PET imaging changes the 
intended patient management strategy in 36.5%, 38% and 49% of cases, 
respectively.[5-7] Results were consistent across all cancer types.[6] A recent 
study by Worsley et al.[8] found that the information derived from PET 
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imaging resulted in a change in intended treatment plans in 50% of 
cases.[8] In up to 90% of cases, referring physicians indicated that PET/
CT enabled them to avoid additional imaging tests or procedures.[7] It 
is largely on this basis that PET can significantly reduce the number of 
tests performed, with substantial healthcare savings if it is done at the 
beginning of the diagnostic pathway rather than as a last resort. PET 
imaging has enabled physicians to avoid costly biopsy and surgery in as 
many as 70% of cases.[5] This can also result in significant cost savings 
and prevent patients from undergoing high-risk surgical procedures.
The South African context
South Africa (SA) is recognised as a world leader in the provision 
of medical isotopes and has centres of global excellence in PET 
for oncology, infection, neurology and personalised medicine.[9] 
SA is among a minority of countries that can provide both 18F-
FDG and non-18F-FDG tracers, including 18F-NAF, 18F-choline, 
68Ga-DOTATATE/DOTATOC, and 68Ga-PSMA for clinical use. We 
have already observed the significant clinical impact of 18F-FDG PET/
CT in the management of cancer patients, similar to that published by 
Hillner et al.[6,7] and Worsely et al.[8]
Evidence is also rapidly accumulating for multiple non-oncological 
indications in the fields of cardiology,[10] neurology[11] and infection 
imaging.[12] This growth is expected to continue with existing tracers, 
and with the numerous possibilities created by new tracers.[13]
The proven clinical effectiveness and growing importance of PET/
CT have prompted the College of Nuclear Physicians (CNP) of the 
Colleges of Medicine of South Africa, in collaboration with university 
hospitals, to develop a list of recommendations on the appropriate 
use of 18F-FDG and non-18F-FDG PET/CT in oncology, cardiology, 
neurology and infection/inflammation. This has resulted in a well-
Table 1. Summary of the appropriate indications for PET/CT
Disease Screening Diagnosis Staging
Restaging/response 
post therapy
Suspected 
recurrence Surveillance
Radiotherapy 
planning
CNS tumours Rs C Rs
Head & neck C Rs Rs R R R
Thyroid Rs Rs Rs
Thymus C C C C
Breast C Rs Rs R
Lymphoma C R Rs Rs C
Langerhans cell histiocytosis C C C C
Multiple myeloma C Rs C Rs C
Carcinoma unknown primary Rs Rs
Paraneoplastic syndrome Rs
Melanoma Rs Rs Rs
Lung cancers Rs Rs C C C
Pleural/mesothelioma C Rs C C
Oesophagus Rs Rs Rs C C
Gastric & pancreas C C C C C
Colorectal and anal Rs Rs R C C
Hepatobiliary C
Sarcoma C Rs C C C C
GIST Rs Rs C
Genitourinary tract cancers C C
Male reproductive system C Rs C C
Female reproductive system Rs Rs Rs C
Non-FDG PET
 Neuroendocrine tumours 
(68Ga-DOTATATE)
C Rs C C C C
Neuroendocrine tumours (18F-FDG) Rs C
Sodium fluoride (18F-NaF) C
 Prostate cancer (18F-choline, 
68Ga-PSMA)
C C C Rs C
Paediatric oncology C Rs Rs C C
Neurology Rs
Cardiology Rs
R = recommended; Rs = recommended in select cases; C = may be considered; GIST = gastrointestinal stromal tumour.
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established list of recommendations on the use of both 18F-FDG and 
non-18F-FDG PET/CT in these fields.
The CNP has focused on defining those clinical conditions 
particular to the SA context, and where PET/CT could potentially 
result in the highest patient impact, with the intention of optimising 
the cost-effectiveness of its utilisation.[14,15] In addition, emphasis 
has been placed on the need for clinical benefit to be demonstrated 
together with accuracy. This principle has also been expressed by 
Schuenemann et al.:[16] ‘If a test fails to improve patient-important 
outcomes, there is no reason to use it, whatever its accuracy.’ This idea 
is not new, and remains one of several steps in establishing diagnostic 
procedures.[17,18] 
Explanation of recommendations
Our recommendations on the appropriate use of PET/CT are 
based on the search for the best clinical evidence in the medical 
literature. In order to achieve consistency and avoid ambiguity, 
recommendations on the use of PET/CT for individual indications 
have been categorised as:
1.   Recommended: PET/CT is generally appropriate for this indi-
cation. There is a strong base of evidence supporting its use and/or 
it is currently recommended by international clinical guidelines.
2.   Recommended in select cases: PET/CT is appropriate for this 
indication in cases meeting clearly defined criteria. In this specific 
context there is a strong base of evidence supporting its use and/or 
it is currently recommended by international clinical guidelines.
3.   May be considered: PET/CT is generally not appropriate for this 
indication; however, it may be appropriate in individual cases 
with a strong motivation. Typically there may be some evidence 
or a strong rationale to support the use of PET/CT in special 
circumstances.
4.   Not recommended: PET/CT is generally not appropriate for this 
indication. Typically there is a low level of evidence and/or weak 
rationale for its use, and it is not endorsed by international clinical 
guidelines.
The recommendations and practical guidelines developed by the CNP 
for the use of 18F-FDG and non-18F-FDG PET/CT are summarised in 
Table 1, and the full details will be available in part 2 of the January 
2016 issue of SAMJ.[19]
Conclusion
It is important to note that it is expected that other clinical situations 
will be added to these recommendations, provided that they are 
based upon solid clinical evidence.
Although the availability of metabolic functional imaging has 
greatly enhanced our understanding of a range of pathological 
processes, and provided new opportunities for incorporation of 
this information into patient management protocols, growth of 
PET globally and in SA is constrained by cost, infrastructure and 
education.[20] The World Heath Organization recommends that 
countries adopt a PET scanner ratio of two scanners per million 
people.[21] This suggests that SA would require approximately 100 
PET scanners – ten times the current number.
Attaining this goal would require a financial commitment 
commensurate with policy priorities that include resources for 
equipment, radiotracer production and distribution, infrastructure, 
and the education of physicians and healthcare consumers. Currently 
this is not achievable.
The cost of PET/CT in SA ranges from ZAR12 000 in the public 
sector to ZAR20 000 in the private sector. With the limited 
resources we have, it is therefore important to avoid the inappro-
priate use of PET/CT. The limited knowledge of PET on the 
part of many referring physicians is a growing concern, and is 
a commonly cited factor contributing to the underutilisation of 
existing PET scanners in some departments. SA doctors tend to 
use PET imaging at the end of the diagnostic pathway, which may 
prevent cost-effective care. Similarly, the inappropriate use of PET/
CT is not cost-effective. There is therefore a need for education and 
training of caregivers, doctors, patients and healthcare officials. The 
CNP recommendations[19] are intended to offer advice regarding 
contemporary applications of PET/CT, as well as indicating novel 
developments and potential future indications. The CNP believes 
that these recommendations will serve an important and relevant 
role in advising referring physicians on the appropriate use of 
18F-FDG and non-18F-FDG PET/CT, which can be a powerful tool 
in patient management in oncology, cardiology, neurology and 
infection/inflammation.
More promising clinical applications will be possible in the future, 
as newer PET tracers become more readily available.
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